NCT05241613View on ClinicalTrials.gov

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

March 5, 2024

Study Completion Date

March 5, 2024

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

AC176

AC176 will be given orally (PO) on a 28-day cycle.

Trial Locations (5)

34232

Site 03, Sarasota

37203

Site 01, Nashville

48201

Site 05, Detroit

75230

Site 04, Dallas

80218

Site 02, Denver

Sponsors
All Listed Sponsors
lead

Accutar Biotechnology Inc

INDUSTRY

NCT05241613 - A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter